Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer

Kim,Yong-Wan; Bae,Su  Mi; Kim,In-Wook; Liu,Hai-Bo; Bang,Hyo  Joo; Chaturvedi,Pankaj  Kumar; Battogtokh,Gantumur; Lim,Hyunsun; Ahn,Woong  Shick

doi:10.3892/or.2012.1829

Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer

Authors:
- Yong-Wan Kim
- Su Mi Bae
- In-Wook Kim
- Hai-Bo Liu
- Hyo Joo Bang
- Pankaj Kumar Chaturvedi
- Gantumur Battogtokh
- Hyunsun Lim
- Woong Shick Ahn
View Affiliations

Affiliations: Catholic Research Institutes of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Gangnam Severance Hospital Biomedical Research Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Published online on: May 22, 2012 https://doi.org/10.3892/or.2012.1829
Pages: 585-591

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to evaluate multiplex liquid assay-based measurement of multiple ovarian cancer-associated biomarkers such as hemoglobin, haptoglobin and apolipoprotein E, together with CA125, which has been widely used in the diagnosis of ovarian cancer, in order to provide a higher diagnostic power. We measured the serum levels of CA125, hemoglobin, haptoglobin and apolipoprotein E from the serum of 76 healthy individuals and 69 ovarian cancer patients using a multiplex liquid assay system, Luminex 100. The results were analyzed according to normal versus ovarian cancer, tumor stages and tumor histology. In addition, to validate the use of these biomarkers for the diagnosis of ovarian cancer, the sensitivity and specificity of each biomarker was analyzed by its receiver operating characteristics (ROC) curve. The serum levels of all four biomarkers in ovarian cancer patients were significantly higher than those of healthy individuals. When CA125 was combined with the biomarkers, the overall sensitivity and specificity were significantly improved in the ROC curve, which showed 95 and 75% sensitivity and specificity, respectively. At 95% specificity for all stages the sensitivity increased to 75% compared to 41% for CA125 alone. For stage I+II increased the sensitivity to 68% from 36% for CA125 alone. For stage III+IV the corresponding values were 100 and 95%, respectively. Taken together, the new combination of hemoglobin, haptoglobin and apolipoprotein E with CA125 significantly improved both the sensitivity and the specificity of ovarian cancer diagnosis compared with those of individual biomarkers. These findings suggest the benefit of the combination of these markers for the diagnosis of ovarian cancer.

View Figures

View References

1	Badgwell D and Bast RC Jr: Early detection of ovarian cancer. Dis Markers. 23:397–410. 2007. View Article : Google Scholar
2	Bast RC Jr: Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc. 115:233–248. 2004.PubMed/NCBI
3	Morice P, Brehier-Ollive D, Rey A, et al: Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol. 14:74–77. 2003. View Article : Google Scholar : PubMed/NCBI
4	Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar
5	Donach M, Yu Y, Artioli G, et al: Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol. 31:209–215. 2010. View Article : Google Scholar : PubMed/NCBI
6	Hensley ML: A step forward for two-step screening for ovarian cancer. J Clin Oncol. 28:2128–2130. 2010. View Article : Google Scholar : PubMed/NCBI
7	Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G and Narod SA: Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol. 20:1570–1577. 2002. View Article : Google Scholar : PubMed/NCBI
8	Tcherkassova J, Abramovich C, Moro R, Chen C, Schmit R and Gerber A: Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumour Biol. 32:831–838. 2011. View Article : Google Scholar : PubMed/NCBI
9	Einhorn N, Sjovall K, Knapp RC, et al: Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 80:14–18. 1992.PubMed/NCBI
10	Aslam N, Ong C, Woelfer B, Nicolaides K and Jurkovic D: Serum CA125 at 11–14 weeks of gestation in women with morphologically normal ovaries. BJOG. 107:689–690. 2000.
11	Menon U and Jacobs IJ: Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol. 12:39–42. 2000. View Article : Google Scholar
12	Predanic M: Differentiating tubal abortion from viable ectopic pregnancy with serum CA-125 and beta-human chorionic gonadotropin determinations. Fertil Steril. 73:522–525. 2000. View Article : Google Scholar : PubMed/NCBI
13	Zhang Z, Bast RC Jr, Yu Y, et al: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64:5882–5890. 2004. View Article : Google Scholar : PubMed/NCBI
14	Gupta D and Lis CG: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovarian Res. 2:132009. View Article : Google Scholar : PubMed/NCBI
15	Jacobs I and Bast RC Jr: The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 4:1–12. 1989.PubMed/NCBI
16	Kim KA, Park CM, Lee JH, et al: Benign ovarian tumors with solid and cystic components that mimic malignancy. AJR Am J Roentgenol. 182:1259–1265. 2004. View Article : Google Scholar : PubMed/NCBI
17	Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H and Comstock GW: Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA. 269:1123–1126. 1993. View Article : Google Scholar : PubMed/NCBI
18	Bast RC Jr, Klug TL, St John E, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309:883–887. 1983. View Article : Google Scholar : PubMed/NCBI
19	Clarke CH, Yip C, Badgwell D, et al: Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol. 122:548–553. 2011. View Article : Google Scholar
20	Woong-Shick A, Sung-Pil P, Su-Mi B, et al: Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer. Cancer Sci. 96:197–201. 2005. View Article : Google Scholar : PubMed/NCBI
21	Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S and Farias-Eisner R: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 5:4589–4596. 2005. View Article : Google Scholar : PubMed/NCBI
22	Beckman G, Eklund A, Frohlander N and Stjernberg N: Haptoglobin groups and lung cancer. Hum Hered. 36:258–260. 1986. View Article : Google Scholar
23	Benkmann HG, Hanssen HP, Ovenbeck R and Goedde HW: Distribution of alpha-1-antitrypsin and haptoglobin phenotypes in bladder cancer patients. Hum Hered. 37:290–293. 1987. View Article : Google Scholar : PubMed/NCBI
24	Abdullah M, Schultz H, Kahler D, et al: Expression of the acute phase protein haptoglobin in human lung cancer and tumor-free lung tissues. Pathol Res Pract. 205:639–647. 2009. View Article : Google Scholar : PubMed/NCBI
25	Mitchell RJ, Carzino R and Janardhana V: Associations between the two serum proteins haptoglobin and transferrin and leukaemia. Hum Hered. 38:144–150. 1988. View Article : Google Scholar : PubMed/NCBI
26	Awadallah SM and Atoum MF: Haptoglobin polymorphism in breast cancer patients form Jordan. Clin Chim Acta. 341:17–21. 2004. View Article : Google Scholar : PubMed/NCBI
27	Dunzendorfer U, Jung K and Ohlenschlager G: Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors. Eur Urol. 6:232–236. 1980.PubMed/NCBI
28	Ye B, Cramer DW, Skates SJ, et al: Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res. 9:2904–2911. 2003.PubMed/NCBI
29	Zhao C, Annamalai L, Guo C, et al: Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia. 9:1–7. 2007. View Article : Google Scholar : PubMed/NCBI
30	Diamandis EP: Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst. 96:353–356. 2004. View Article : Google Scholar : PubMed/NCBI
31	Ahmed N, Barker G, Oliva KT, et al: Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer. 91:129–140. 2004. View Article : Google Scholar : PubMed/NCBI
32	Hough CD, Sherman-Baust CA, Pizer ES, et al: Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60:6281–6287. 2000.PubMed/NCBI
33	Chen YC, Pohl G, Wang TL, et al: Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res. 65:331–337. 2005.PubMed/NCBI
34	Shih Ie M and Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 164:1511–1518. 2004.PubMed/NCBI
35	McIntosh MW, Drescher C, Karlan B, et al: Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 95:9–15. 2004. View Article : Google Scholar : PubMed/NCBI
36	Rosen DG, Wang L, Atkinson JN, et al: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 99:267–277. 2005. View Article : Google Scholar : PubMed/NCBI
37	Anderson GL, McIntosh M, Wu L, et al: Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 102:26–38. 2010. View Article : Google Scholar : PubMed/NCBI
38	Palmer C, Duan X, Hawley S, et al: Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One. 3:e26332008. View Article : Google Scholar : PubMed/NCBI
39	Yurkovetsky Z, Skates S, Lomakin A, et al: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 28:2159–2166. 2010. View Article : Google Scholar : PubMed/NCBI
40	Zhang B, Barekati Z, Kohler C, et al: Proteomics and biomarkers for ovarian cancer diagnosis. Ann Clin Lab Sci. 40:218–225. 2010.PubMed/NCBI
41	West-Norager M, Kelstrup CD, Schou C, Hogdall EV, Hogdall CK and Heegaard NH: Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J Chromatogr B Analyt Technol Biomed Life Sci. 847:30–37. 2007. View Article : Google Scholar : PubMed/NCBI
42	Liu MY, Xydakis AM, Hoogeveen RC, et al: Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem. 51:1102–1109. 2005. View Article : Google Scholar : PubMed/NCBI